(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -13.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.03%.
Nektar Therapeutics's revenue in 2026 is $54,589,000.On average, 14 Wall Street analysts forecast NKTR's revenue for 2026 to be $1,455,242,690, with the lowest NKTR revenue forecast at $1,370,226,635, and the highest NKTR revenue forecast at $1,613,256,467. On average, 14 Wall Street analysts forecast NKTR's revenue for 2027 to be $1,301,155,358, with the lowest NKTR revenue forecast at $271,027,086, and the highest NKTR revenue forecast at $1,530,903,565.
In 2028, NKTR is forecast to generate $1,223,411,761 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,890,955,588.